Journal
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
Volume 14, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13223-018-0280-7
Keywords
-
Categories
Funding
- AstraZeneca
- Boehringer Ingelheim
- CSL Behring Canada Inc.
- MEDA Pharmaceuticals Ltd.
- Merck Canada Inc.
- Pfizer Canada Inc.
- Shire Pharma Canada ULC
- Stallergenes Greer Canada
- Takeda Canada
- Teva Canada Innovation
- Aralez Tribute
- Pediapharm
Ask authors/readers for more resources
Allergic rhinitis is a common disorder that is strongly linked to asthma and conjunctivitis. It is usually a long-standing condition that often goes undetected in the primary-care setting. The classic symptoms of the disorder are nasal congestion, nasal itch, rhinorrhea and sneezing. A thorough history, physical examination and allergen skin testing are important for establishing the diagnosis of allergic rhinitis. Second-generation oral antihistamines and intranasal corticosteroids are the mainstay of treatment. Allergen immunotherapy is an effective immune-modulating treatment that should be recommended if pharmacologic therapy for allergic rhinitis is not effective or is not tolerated, or if chosen by the patient. This article provides an overview of the pathophysiology, diagnosis, and appropriate management of this disorder.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available